Theriva Biologics Inc. (TOVX) - Total Assets
Based on the latest financial reports, Theriva Biologics Inc. (TOVX) holds total assets worth $38.25 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Theriva Biologics Inc. - Total Assets Trend (1993–2025)
This chart illustrates how Theriva Biologics Inc.'s total assets have evolved over time, based on quarterly financial data. Also see market cap of Theriva Biologics Inc. for the company's overall valuation and market capitalisation.
Theriva Biologics Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Theriva Biologics Inc.'s total assets of $38.25 Million consist of 45.7% current assets and 54.3% non-current assets. Review how much debt does Theriva Biologics Inc. carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.1% |
| Accounts Receivable | $3.83 Million | 10.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $19.62 Million | 51.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1993–2025)
This chart illustrates how Theriva Biologics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Theriva Biologics Inc. for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theriva Biologics Inc.'s current assets represent 45.7% of total assets in 2025, a decrease from 94.4% in 1993.
- Cash Position: Cash and equivalents constituted 34.1% of total assets in 2025, down from 94.4% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is intangible assets at 51.3% of total assets.
Theriva Biologics Inc. Competitors by Total Assets
Key competitors of Theriva Biologics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Theriva Biologics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.63 | 1.53 | 36.05 |
| Quick Ratio | 1.63 | 1.53 | 36.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.49 Million | $4.33 Million | $73.53 Million |
Theriva Biologics Inc. - Advanced Valuation Insights
This section examines the relationship between Theriva Biologics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.14 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | 8.2% |
| Total Assets | $38.24 Million |
| Market Capitalization | $10.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values Theriva Biologics Inc.'s assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Theriva Biologics Inc.'s assets grew by 8.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Theriva Biologics Inc. (1993–2025)
The table below shows the annual total assets of Theriva Biologics Inc. from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $38.24 Million | +8.17% |
| 2024-12-31 | $35.35 Million | -35.98% |
| 2023-12-31 | $55.22 Million | -23.16% |
| 2022-12-31 | $71.86 Million | +2.13% |
| 2021-12-31 | $70.36 Million | +736.68% |
| 2020-12-31 | $8.41 Million | -51.20% |
| 2019-12-31 | $17.23 Million | -42.82% |
| 2018-12-31 | $30.14 Million | +60.00% |
| 2017-12-31 | $18.84 Million | -16.27% |
| 2016-12-31 | $22.50 Million | -27.06% |
| 2015-12-31 | $30.84 Million | +61.12% |
| 2014-12-31 | $19.14 Million | +17.76% |
| 2013-12-31 | $16.26 Million | +21.11% |
| 2012-12-31 | $13.42 Million | +79.55% |
| 2011-12-31 | $7.48 Million | +81.85% |
| 2010-12-31 | $4.11 Million | +0.87% |
| 2009-12-31 | $4.08 Million | -44.81% |
| 2008-12-31 | $7.39 Million | -45.83% |
| 2007-12-31 | $13.63 Million | +8.93% |
| 2006-12-31 | $12.52 Million | +769.17% |
| 2005-12-31 | $1.44 Million | -4.93% |
| 2002-12-31 | $1.51 Million | -26.34% |
| 2001-12-31 | $2.06 Million | -62.27% |
| 2000-12-31 | $5.45 Million | +7.96% |
| 1999-12-31 | $5.05 Million | +74.09% |
| 1998-12-31 | $2.90 Million | +314.29% |
| 1997-12-31 | $700.00K | -75.00% |
| 1996-12-31 | $2.80 Million | +27.27% |
| 1995-12-31 | $2.20 Million | +450.00% |
| 1994-12-31 | $400.00K | -77.78% |
| 1993-12-31 | $1.80 Million | -- |
About Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcin… Read more